MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) has announced the completion and delivery of its first Edge AI Intoxication and Fatigue Detection Kiosk prototypes, marking a significant step in commercializing voice-based impairment detection technology for workplace safety. The kiosks leverage artificial intelligence to analyze short voice samples, examining more than 140 acoustic markers associated with potential alcohol, drug, or fatigue-related impairment. The AI models have been trained on over 50 million data points, aiming to provide a non-invasive and rapid screening method.
The prototypes are now entering testing, validation, and data-analysis phases involving industry participants, speech specialists, and software engineers. This phase is critical for refining the predictive models and assessing real-world performance. MindBio is targeting safety-sensitive industries such as mining, aviation, construction, transportation, and law enforcement, where large workforces and operational risks make conventional testing methods—like breath, saliva, urine, and laboratory tests—costly and time-consuming. The company's approach is designed to offer a rapid, scalable, and less invasive initial screening, with individuals flagged for potential impairment able to undergo additional evaluation using established testing protocols.
According to the company, the AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy using just the human voice. The enterprise platform includes Edge-AI kiosks integrating bespoke hardware and software for detecting drug and alcohol intoxication in various enterprise environments. This technology could revolutionize workplace safety by enabling frequent, non-invasive screening that can be deployed quickly across large workforces.
The implications of this announcement are substantial for industries where impairment is a critical safety concern. Traditional methods often require time-consuming sample collection and laboratory analysis, which can delay results and reduce the frequency of testing. MindBio's kiosks could allow for real-time screening at entry points or shift changes, potentially preventing accidents caused by impaired workers. The scalability of the technology—using voice samples that can be collected in seconds—makes it feasible to screen large numbers of employees regularly without significant disruption.
MindBio Therapeutics is a biotechnology company commercializing AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company's focus on safety-sensitive industries highlights the potential for this technology to reduce workplace accidents and improve overall safety compliance. For more information, visit the company's website at www.MindBioTherapeutics.com.
